Six services, one entry point

Readiness diligence covers what your next investor will review

• Science Development state of the lead programme and the pipeline.
• Clinical and regulatory The path to the next milestone.
• Intellectual property Ownership, licences, filings, freedom-to-operate questions.
• Corporate Entity, governance, cap table and material contracts.
• Financials Plan, budget, use of funds and runway.
• Calibration Every area judged at the bar of the round being prepared.

The readiness diligence delivers three documents

• Readiness assessment Scored by area, with the gaps ranked by their effect on the round.
• Document request list The documents that are missing, listed for the company to supply.
• Remediation plan What to fix, in what order, and who does it.

A data room built to answer before they ask

• Structure Set up against a sell-side readiness checklist.
• Open items Tracked as documents arrive, with a dated readiness memo at each review.
• Development section Scored on its own, against what an R&D diligence asks for.

• Market sizing Built bottom-up from its drivers, with every assumption stated.
• Competitor landscape A capability comparison across the programmes that matter.
• Scenarios Each scenario carries a stated probability.
• Regulatory research The rules and pathways the plan relies on: Swiss, EU, EMA and FDA.

Fractional CFO: planning and analysis first

The finance work investors test first is planning: whether the model holds, whether the budget follows the development plan, and how long the cash lasts if a milestone slips.

• 01 Financial model Driver-based, built from the development plan, refreshed with actuals each period.
• 02 Use of funds A milestone budget, with each line tied to the milestone it pays for.
• 03 Scenarios Base, delay and downside cases, with the cash low point and decision dates.
• 04 Cash forecast A 13-week cash forecast when cash is tight.
• 05 Round analysis Round sizing against milestones, dilution across rounds, valuation analysis for the round.
• 06 Grant budgets Budgets for grant and other non-dilutive funding applications.

Fractional CFO: reporting, with accounting in support

• 01 Reporting Monthly management and board reporting: KPIs, variance against budget, burn and runway. Investor reporting once the round has closed.
• 02 Accounting We run the monthly close where there is no finance function. Otherwise we work from the company's books, alongside its finance lead.

Fractional CMO: building confidence in your development strategy

• 01 Ready for investor and partner diligence We help you address the clinical questions that shape investment and partnering decisions: Why this indication? Why this patient population? What supports the proposed dose and trial design? What will the first clinical study establish, and what comes next?
• 02 Experienced medical leadership, tailored to your programme A physician scientist who has twice served as a biotech Chief Medical Officer joins as your fractional CMO. We define the scope around your programme's stage, critical decisions and internal capabilities, providing continuity from preclinical development into early clinical execution.

Fractional CMO: leading early clinical development

• 01 Development strategy and decision-making We refine the development plan as evidence emerges, integrating clinical findings, biomarkers and benefit-risk assessments to guide dose selection, patient populations, subsequent studies and go/no-go decisions.
• 02 Clinical oversight and safety We provide medical oversight alongside your internal teams and external partners, covering trial execution, safety governance, enrolment, data quality and interpretation of results.

• Board packs Board packs and decision points, prepared ahead of each meeting.
• Board seat A board or observer seat for one of us, where the company and LSI agree on it.